ARTESIA NEWSLETTER

March 2021

Dear colleagues,
After a long journey, we now have fewer than 300 patients left to enroll in the ARTESIA trial. Our results will help guide the management of pacemaker and ICD patients with SCAF and will help us to better understand how to conduct AF screening in the community. Despite the COVID-19 pandemic, we have seen an increase in enrollment over the last few weeks, which is common at the end of large clinical trials. We are so close to the finish line that a mere 2 more patients from each centre would complete enrollment. Please be on the lookout for eligible patients, including patients that may have been identified during the past 6 months that may have declined study participation until after vaccination. We will finish enrollment sometime this summer, so please try and include your eligible patients before then. Renato and I look forward to celebrating this milestone with you in person very soon!

Dr. Jeff Healey, Dr. Renato Lopes & Dr. Marco Alings

Global Enrollment

3713

Patients to GO!

287

Follow us on Social Media @ ARTESiA_RCT

ARTESiA Website: www2.phri.ca/ARTESiA

COUNTRY HIGHLIGHTS

Congratulations to Dr. Juan Benezet Mazuecos and Study Team for enrolling the 400th patient in Spain! Thank you for your continued support and dedication to the ARTESiA study we truly appreciate it.

Congratulations to Dr. Andrew Kaplan along with Study Coordinators Adam Gitkin and Tawni Oyler on enrolling their 100th patient, and we couldn't be happier for them! The staff are a pleasure to work with and the dedication they show each and everyday to their patients is truly admirable.

Top 5 Enrolling Sites

101Pts		Dr. Andrew Kaplan - CardioVascular Associates of Mesa
91Pts		Dr. Marta Pombo - Hospital Costa del Sol
84Pts		Dr. Felix Ayala-Paredes - CHUS - Hopital Fleurimont
76Pts		Dr. Guy Amit - Hamilton General Hospital
74Pts		Dr. Peter Leong-Sit - London Health Sciences Center

PATIENT FOLLOW-UP

Since ARTESIA is the intention to treat trial, we continue to collect patient's data and monitor them for potential SAEs and outcome events in the same manner as those patients who are still on study drug. The follow up visits should be completed in the same way as other trial participants and would be paid as a regular 'Completed' visit. Even though the patient has discontinued the study drug, we still want to follow the patient and the remainder of their study visits should occur as scheduled. **Completed visits can be in person, by phone with the patient directly, or with family/ friend , through health records, primary care physician etc.** Once the follow up visit is done you can then complete e-CRFs on iDatafax